EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint (Nasdaq:EYPT) granted non-statutory stock options as NASDAQ Listing Rule 5635(c)(4) inducement awards to two new employees on July 15, 2026.

Rhea-AI Summary

EyePoint (Nasdaq:EYPT) granted non-statutory stock options as NASDAQ Listing Rule 5635(c)(4) inducement awards to two new employees on July 15, 2026. The options cover up to 63,500 common shares at an exercise price of $13.85, have a ten-year term, and vest over four years, subject to continued service.

Positive

• 63,500 inducement options granted to support hiring two new employees
• Options priced at $13.85, equal to the July 15, 2026 closing price
• Four-year vesting with 10-year term ties equity to continued service

Negative

• New option grants for 63,500 shares create incremental potential dilution for existing shareholders

News Explained

The July 16, 2026 release reports completed inducement grants outside EyePoint’s 2023 Long-Term Incentive Plan; the options give two new employees a future right to purchase up to $63,500 shares, which could change ownership if exercised.

Argus Jul 16 session 8 alerts

-5.85% close to close 1.0x rel. volume Open Argus

Details

Market reaction after July 2026 inducement option grants: EYPT -5.85% in the Jul 16 session

+3.2% Peak Tracked

-2.7% Trough Tracked

$1.16B Market Cap

In the Jul 16 session, EYPT declined 5.85%, reflecting a notable negative market reaction. Argus tracked a peak move of +3.2% during that session. Argus tracked a trough of -2.7% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.8% in the session following this news. A sharp decline following this grant could...

Analysis

The stock moved -5.8% in the session following this news. A sharp decline following this grant could be viewed against the moderate short-interest signal and recent insider net selling of 7,312 shares, which may sensitize investors to equity-based compensation and potential dilution, even when grants are relatively small.

Key Figures

Inducement options: 63,500 shares Exercise price: $13.85 per share Option term: 10 years +3 more

Inducement options

63,500 shares

Aggregate stock options granted to new employees

Exercise price

$13.85 per share

Grant price equal to July 15, 2026 closing price

Option term

10 years

Duration of inducement stock options granted July 15, 2026

Vesting period

4 years

Options vest over four years subject to continued service

Initial vesting

25% of shares

Vests on first anniversary of each employee’s grant date

Employee recipients

2 employees

Number of new employees receiving inducement option awards

Historical Context

5 past events · Latest: Jul 13

5 events

1. Jul 13

   Leadership appointment

   24h Move

   -3.0%

   Appointment of Chief Strategic Science Officer with stock option grant.

2. Jun 16

   Inducement option grants

   24h Move

   +6.6%

   Inducement stock options for three new employees under NASDAQ Rule 5635(c)(4).

3. May 19

   Investor conferences

   24h Move

   +1.0%

   Participation in multiple upcoming ophthalmology and healthcare investor conferences.

4. May 18

   Inducement option grants

   24h Move

   -5.3%

   Inducement stock options for eight new employees outside 2023 plan.

5. May 14

   Phase 3 DSMC update

   24h Move

   -1.4%

   Third positive DSMC recommendation for Phase 3 DURAVYU wet AMD trials.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), non-statutory stock options, exercise price, vesting

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-statutory stock options financial

"announced that the Company granted non-statutory stock options to new employees as inducement awards"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

exercise price financial

"The option awards have an exercise price of $13.85 per share, the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company granted stock options to purchase up to an aggregate of 63,500 shares of EyePoint common stock to two new employees. The stock options were granted on July 15, 2026. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $13.85 per share, the closing price of EyePoint’s common stock on July 15, 2026. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continued service with EyePoint through the applicable vesting dates.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Topline data is expected for wet AMD beginning in mid-2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU^™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com

Media:
Helen O’Gorman
FTI Consulting
helen.ogorman@fticonsulting.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement stock option grants did EyePoint (EYPT) announce on July 16, 2026?

EyePoint announced non-statutory stock options covering up to 63,500 shares for two new employees. According to EyePoint, these awards were granted as inducement grants under NASDAQ Listing Rule 5635(c)(4) and made outside the company’s 2023 Long-Term Incentive Plan.

What is the exercise price of EyePoint’s July 15, 2026 inducement options for EYPT?

The inducement stock options have an exercise price of $13.85 per share. According to EyePoint, this price equals the closing price of EyePoint common stock on July 15, 2026, the grant date for the options awarded to the two new employees.

How do EyePoint’s July 2026 inducement option grants (EYPT) vest over time?

The options vest over four years, with 25% vesting on the first anniversary of the grant date. According to EyePoint, the remaining 75% vests in equal monthly installments over the following three years, subject to the employee’s continued service with the company.

Why were EyePoint’s 63,500 EYPT options granted outside the 2023 Long-Term Incentive Plan?

The options were granted as inducement awards to two new employees under NASDAQ Listing Rule 5635(c)(4). According to EyePoint, issuing them outside the 2023 Long-Term Incentive Plan supports hiring by providing equity incentives material to employment acceptance.

What is the term of EyePoint’s July 15, 2026 inducement stock options for EYPT shares?

The inducement stock options have a ten-year term from the grant date. According to EyePoint, the options remain exercisable for this ten-year period, subject to standard conditions, including the employee’s continued service and the vesting schedule tied to employment duration.

Who approved EyePoint’s July 2026 inducement stock option grants for EYPT?

The grants were approved by EyePoint’s Compensation Committee. According to EyePoint, the committee authorized these non-statutory stock option awards as inducement grants for two new employees, consistent with NASDAQ Listing Rule 5635(c)(4) requirements for equity compensation outside shareholder-approved plans.